STAT+: Death of patient in closely watched Alzheimer’s trial raises concern about risk for some groups
The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical…
Category: STAT+
STAT+: Drugmaker raises the price of an old chemo medicine tenfold amid persistent shortages
Amid sporadic shortages of a drug that is essential in preparing patients for lifesaving, cancer-fighting…
STAT+: A new suite of RNA-sensing tools could help scientists target cancerous cells, and much more
Sure, you’ve heard of CRISPR. But it’s 2022. The acronym you need to know now…
STAT+: Pharmalittle: Italy probes Pfizer over profit transfers; FDA postpones meeting for OTC birth control pill
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Republican ideas to reform Medicare could rile health care industry
WASHINGTON — Democrats are suddenly blasting Republicans on the campaign trail over a surprising new…
STAT+: Pharmalittle: White House pharma help in plan to combat hepatitis C; J&J blood cancer drug will cost $39,500 a month
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
Biotech’s newest odd couple: A pharma insider and a music maven launch a health care VC
D.A. Wallach’s first meeting with his business partner could have been the setting of a…
STAT+: Q&A: A health justice lawyer and new MacArthur ‘genius’ on pharma’s patent games
Priti Krishtel has had it with the patent tricks up pharma’s sleeves. The co-executive director…
STAT+: Pacific Biosciences, known for niche DNA sequencing, looks to rival Illumina with new product launch
Pacific Biosciences, a Menlo Park, Calif., firm best known for its niche approach to DNA…
STAT+: Merck fined $39 million by Spain’s antitrust regulator for ‘serious’ violation
The antitrust regulator in Spain has fined Merck approximately $39 million for preventing a competitor…
STAT+: Normunity launches with $65 million to unleash the immune system on tumors
Our best weapon against cancer may already live inside us — it just needs a…
STAT+: Pharmalittle: Online prescribing prompts scrutiny and concern; FDA is pushed to approve OTC birth control pills
Top of the morning to you. Gray skies are hovering once again over the Pharmalot…
STAT+: Pharma companies are investing in online prescribing. Who’s keeping watch?
Over the course of the pandemic, online prescribing has been embraced as a powerful tool…
STAT+: Pharmalittle: Merck suddenly finds Ebola vaccine doses in its freezers; drugs studied to combat women’s midlife mood swings
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Epic’s overhaul of a flawed algorithm shows why AI oversight is a life-or-death issue
Epic, the nation’s dominant seller of electronic health records, was bracing for a catastrophe. It…
STAT+: Inside Michelle McMurry-Heath’s departure from BIO: Firings, internal clashes, and a pivotal job review
WASHINGTON — Only two years ago, Michelle McMurry-Heath was named chief executive of BIO, the…
STAT+: Pharmalittle: Pfizer plans to quadruple price of its Covid-19 vaccine; pharma pushed to tie exec compensation to access to meds
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
STAT+: Novartis agrees to license a best-selling cancer drug to dozens of low- and middle-income countries
Amid a push to widen access to medicines to poor countries, Novartis has reached an…
STAT+: How one pharma insider sees the drug pricing reform law: the impact will ‘vary by product and by company’
After years of stops and starts, a law was finally passed in Congress this summer…
STAT+: Pharmalittle: Pharma tries to blunt Medicare power to negotiate prices; FDA panel supports withdrawal of premature birth drug
Top of the morning to you. Another deliciously shiny day is unfolding over the Pharmalot…
STAT+: As AI grows in medical image analysis, concern about building trust with doctors grows too
In 2018, the researcher Pranav Rajpurkar was working on an algorithm that could find blood…
STAT+: Large insurer’s decision to cover some prescription digital therapies may be a milestone for app makers
A large commercial insurer’s decision to cover a controversial class of software-based treatments for psychiatric…
STAT+: FDA panel votes that a controversial premature birth medication should be withdrawn
After an extraordinary three-day hearing, an expert panel of advisers to the U.S. Food and…
STAT+: Pharmalittle: Merck KGaA probed by French court for misleading info; former Genentech scientists given prison terms over trade-secret theft
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
Opinion: STAT+: How digital health innovators can successfully navigate evolving FDA regulations
In the rapidly changing landscape of digital health, innovation has often outpaced regulations, especially for…
STAT+: How many? A new analysis finds 1.3 million American adults rationed insulin due to cost
Amid ongoing controversy over the cost of insulin, a new analysis finds that approximately 1.3…
STAT+: Pharmalittle: J&J will cut its workforce; pharma gave Dems money despite threats over Medicare drug-price negotiation
Top of the morning to you. Another busy day is unfolding on the Pharmalot satellite…
STAT+: Despite its threats, PhRMA is still supporting Democrats who voted for Medicare negotiation
Drugmakers’ powerhouse lobby did not exactly make good on its early August threat to hold…
.jpg)
STAT+: Pharmalittle: BioNTech eyes cancer vaccine before decade’s end; Pfizer asks Supreme Court to review copay programs
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Josh Bilenker’s last biotech sold for $8 billion. His next one is cloaked in mystery but loaded with money
Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No…
STAT+: Milestone Pharma’s nasal spray rapidly restores normal heart rhythm, achieving goal of key study
Milestone Pharmaceuticals said Monday that an experimental nasal-spray medicine acted quickly to treat people experiencing…
STAT+: What to know about Roche’s experimental Alzheimer’s treatment
The next big Alzheimer’s disease study readout is almost here. Roche is nearing the completion…
STAT+: European Prosecutor’s Office confirms it’s investigating European Union Covid vaccine contracts
In an unusual step, the European Public Prosecutor’s Office (EPPO) confirmed it has opened an…
STAT+: UnitedHealth plots further growth in its profitable provider division
Insurance giant UnitedHealth Group’s strong financial showing in the third quarter was driven in part…
STAT+: Lawmakers push NIH to disclose steps being taken to ensure clinical trial results are reported
A group of Republican senators is demanding to know what steps the U.S. National Institutes…
STAT+: Pharmalittle: Biden to sign executive order to push drug costs down; big grocers get bad grades for antibiotic policies
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Documents detail how pharmacy giants Walgreens, CVS, and Walmart failed patients in the opioid epidemic
In 2011, Walgreens executives were under pressure. Amid a growing addiction crisis, and with the…
STAT+: AstraZeneca is fined by South Korea for an anticompetitive deal over a cancer drug
South Korea’s anti-trust regulator has fined AstraZeneca and a local generic drugmaker a total of…
STAT+: Pharmalittle: GSK vaccine for RSV was effective in study of older adults; Eisai is confident of U.S. approval of its Alzheimer’s drug
Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the…
STAT+: Relmada antidepressant drug fails first of several late-stage clinical trials
Relmada Therapeutics said Thursday that its experimental treatment for depression failed to achieve the primary…
STAT+: Flush with cash from Covid-19 vaccine, BioNTech founders have outsized ambitions
BOSTON — BioNTech CEO Uğur Şahin had been in marathon meetings since he arrived in…
STAT+: Alphabet’s AI predicted the structure of 200 million proteins. Can it really speed up drug discovery?
Every two years since 1994, scientists have come together for an experiment — better described…
STAT+: Differences in countries’ regulations keep some cell and gene therapies from reaching patients
CARLSBAD, Calif. — Biotech companies developing cutting-edge cell and gene therapies often are tripped up…
STAT+: Merck pays $250 million to license a Moderna skin-cancer vaccine candidate
Merck on Wednesday agreed to extend an ongoing collaboration with Moderna to develop a personalized…
STAT+: FDA and large compound pharmacies settle a long-running dispute over a key list for ingredients
The U.S. Food and Drug Administration and a trade group that represents large compound pharmacies…
STAT+: Pharmalittle: Walmart joins rivals in entering clinical trial work; Maiden Pharma failed to do quality tests on cough syrups
Top of the morning to you, and a fine one it is. After all, there…
STAT+: Triplet Therapeutics, biotech company focused on Huntington’s, quietly shuts down
A biotech company co-founded by venture capital firm Atlas Venture has shut down after running…
STAT+: Even as large health systems bleed money, children’s hospitals are faring well
Children’s hospitals were spared from the worst ravages of the pandemic, putting them in a…
STAT+: Bright exits ACA health insurance marketplaces to stay afloat
Bright Health Group is drastically cutting back its health insurance offerings for next year, including…
STAT+: Pharmalittle: BIO CEO resigns amid board disagreements; Pfizer exec denies allegations over EU Covid-vaccine deal
Good morning, everyone, and how are you today? We are doing just fine thank you,…